Neoantigen cancer vaccines have been envisioned as one of the most promising means for
cancer therapies. However, identifying neoantigens for tumor types with low tumor mutation …

Personalized cancer vaccines targeting specific neoantigens have been envisioned as one
of the most promising approaches in cancer immunotherapy. However, the physicochemical …

Despite years of preclinical efforts and hundreds of clinical studies, therapeutic cancer
vaccines with the routine ability to limit or eliminate tumor growth in humans have been …

Background Personalized cancer vaccines based on neoantigens have reached the clinical
trial stage in melanoma. Different vaccination protocols showed efficacy in preclinical …

Neoantigens arising from tumor-specific genomic alterations constitute authentic non-self
antigens and represent a new class of targets for cancer immunotherapy. Recent reports on …

Recent advances in several areas are rekindling interest and enabling progress in the
development of therapeutic cancer vaccines. These advances have been made in target …

Background Harnessing the immune system to purposely recognize and destroy tumors
represents a significant breakthrough in clinical oncology. Non-synonymous mutations …

Cancer vaccines, which are designed to amplify tumour-specific T cell responses through
active immunization, have long been envisioned as a key tool of effective cancer …

Introduction Cancer vaccine represents a promising strategy toward personalized
immunotherapy, and its therapeutic potency highly relies on the specificity of tumor antigens …

Immunotherapy represents a promising strategy for cancer treatment that utilizes immune
cells or drugs to activate the patient's own immune system and eliminate cancer cells. One of …